Try our beta test site

ICS/LABA Adherence and COPD Exacerbation

This study has been completed.
Sponsor:
Collaborator:
Healthcore
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT02446041
First received: May 13, 2015
Last updated: October 10, 2016
Last verified: October 2016
  Purpose
The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adherent.

Condition Intervention
Pulmonary Disease
Chronic Obstructive
Other: Non-Interventional Study

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Adherence and COPD Exacerbation Rates in Patients Initiating ICS/LABA Therapy.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Exacerbation rate [ Time Frame: 12 months ]
    Rate of COPD exacerbation occurring during the 12 months after therapy initiation.


Secondary Outcome Measures:
  • Severe Exacerbation rate [ Time Frame: 12 months ]
    Severe exacerbation rate during the 12 months after therapy initiation


Other Outcome Measures:
  • Time to Exacerbation [ Time Frame: 12 months ]
    Time to first COPD exacerbation during the 12 months after therapy initiation.


Enrollment: 10000
Study Start Date: May 2015
Study Completion Date: October 2015
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
ICS/LABA Patients
ICS/LABA Patients following standard of care
Other: Non-Interventional Study
Non-Interventional Study

Detailed Description:
This retrospective, observational study will assess the effectiveness of ICS/LABA combination therapies among COPD patients new to the ICS/LABA combination therapies in the US, comparing those who are adherent to the index medication and those who are non-adherent. Adherence will be measured using the proportion of days covered with the index medication. Medical and pharmacy claims data will be used as the data source.
  Eligibility

Ages Eligible for Study:   40 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
ICS/LABA patients with administrative claims data from health plans in the Northeast, Midwest, South and West United States.
Criteria

Inclusion Criteria:

  • at least one prescription fill for ICS/LABA combination during identification period.
  • COPD diagnosis
  • 40 years or older at index date
  • > or = 12 months of continuous health plan enrollment prior to and following index date
  • 1 or more prescription for SABA, SAMA or SABA/SAMA during the pre-index period.

Exclusion Criteria:

  • Patients with prescription claim for ICS/LABA combination therapy during the 12 month pre-index period
  • Patients receiving oral corticosteroid medication for more than 180 days during the 12 month pre-index period
  • Patients with cancer diagnosis in 12 month pre-index period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02446041

Locations
United States, Delaware
Research Facility
Wilmington, Delaware, United States
Sponsors and Collaborators
AstraZeneca
Healthcore
Investigators
Study Chair: Frank Trudo, MD AstraZeneca
  More Information

Additional Information:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02446041     History of Changes
Other Study ID Numbers: D589BR00034
Study First Received: May 13, 2015
Last Updated: October 10, 2016

Keywords provided by AstraZeneca:
COPD
Chronic Bronchitis
Pulmonary Emphysema

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on March 24, 2017